Related Experiment Video

Updated: Jun 25, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational

Rebecca C Ahrens-Nicklas1, Colleen E Clancy, David J Christini

  • 1Greenberg Division of Cardiology, Weill Cornell Medical College, 1300 York Ave., Box 161, New York, NY 10065, USA.

Cardiovascular Research
|March 7, 2009
PubMed
Abstract

Insights

Beta-adrenergic activation may protect against Long QT syndrome type 3 (LQT3) by reducing dangerous heart rhythms. Further clinical studies are needed to confirm if beta-blockers are effective for LQT3 patients.

Area of Science:

  • Cardiology
  • Computational Biology
  • Pharmacology

Background:

  • Long QT syndrome (LQTS) is a group of inherited cardiac conditions.
  • LQTS increases the risk of sudden cardiac death.
  • Beta-adrenergic blockers are standard LQTS treatment, but their efficacy in LQT3 is unclear.

Purpose of the Study:

  • To investigate the effects of beta-adrenergic drugs on the LQT3 phenotype.
  • To explore the reasons for ambiguous results in previous studies on beta-blockers for LQT3.

Main Methods:

  • Developed a computational model of LQT3 mutant guinea pig ventricular myocytes.
  • Incorporated beta-agonist and beta-blocker effects into the model.
  • Analyzed the impact on arrhythmogenic phenomena like dispersion of repolarization and early afterdepolarizations.

Main Results:

  • Beta-adrenergic activation dose-dependently suppressed transmural dispersion of repolarization and early afterdepolarizations.
  • The effectiveness of beta-activation in preventing conduction block was dependent on pacing rate.
  • Low-dose propranolol reversed beneficial effects, while high doses showed some antiarrhythmic effects.

Conclusions:

  • Beta-adrenergic activation may offer protection in LQT3.
  • Findings help reconcile conflicting experimental results.
  • Emphasizes the need for clinical trials to re-evaluate beta-blocker use in LQT3.

More Related Videos

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...